Questions discussed in this category
A female in her early 70s, total thyroidectomy, left 1.4 cm and right 0.7 cm tall cell variant papillary thyroid cancer with clear margins and negativ...
What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?
What techniques and doses would you prescribe to the primary and regional nodes?
Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?
Patient does not have hypercalcemia.
What factors may favor RET inhibition versus observation?
Would you elect for concurrent chemoRT or RT alone?
In addition to TSH suppression, would you opt for RAI, targeted treatment based off NGS, or lenvatinib?
A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.
Such as in patients who are elderly or have borderline performance status
Aggressive histology with tall cell variant papillary thyroid carcinoma that's progressed 2 months after RAI and while on TSH suppression, without tra...
If not, what is your thyroid hormone withdrawal protocol? If so, would you still treat a patient with possibly metastatic disease?
221982156520370202841994519223803018835155211757010189107818963843084276906658754771997
Papers discussed in this category
N. Engl. J. Med., 2012-05-03
N. Engl. J. Med., 2012-05-03
The New England journal of medicine, 2015-02-12
Cancer discovery, 2015-07
J Immunother Cancer,
Thyroid : official journal of the American Thyroid Association, 2020 May 07
Journal of thyroid research, 2020 Apr 14